Research digest / about
About This CJC-1295 Digest
What lights up on this board, what stays off it, and how the record is handled.
What Online CJC-1295 is
Online CJC-1295 is a night-board for one compound's evidence: the peer-reviewed CJC-1295 literature, lit tile by tile. Nobody here runs a clinic or writes prescriptions, there is no pharmacy counter and no cart, and none of the text is medical advice — it is a sourced reading of published science and nothing else.
The board lays the record out by weight: the GH/IGF-1 axis pharmacokinetics, the DAC albumin-conjugation chemistry, the animal proof-of-concept, and the regulatory status. Landmark findings burn brightest as featured tiles, supporting identifiers sit in smaller cells, and the honest gaps are left deliberately dark rather than papered over. Every quantitative claim is wired to a numbered citation that resolves to a real study on the references page.
What the name means
The "online" in the name is editorial framing — a position this publisher occupies relative to the literature, a place to read the research, not a storefront and not a checkout. We do not sell CJC-1295, we do not source it, and we do not point readers to anyone who does. The word describes a reading surface for an accessible, plain-language digest of what the published research shows; it is not a claim about products or services.
This distinction matters because much of what is written about CJC-1295 online is promotional. This site is the opposite: it reports what specific studies measured, names where the human data stop, and keeps the DAC and no-DAC forms carefully apart, since conflating them is the most common error in the popular coverage.
How we handle the record
We lead with the finding and attribute it to the study that produced it. Where the evidence is strong — the 5.8-8.1 day DAC half-life, the multi-day GH and IGF-1 elevation, the preserved pulsatility — we say so plainly. Where it is thin — no large efficacy trial, no long-term safety data, no validated human dose, a discontinued development program — we say that just as plainly, and we mark it on the page rather than burying it.
CJC-1295 is not approved for human use, and nothing on this site is a dosing recommendation or a course of treatment. Doses and routes are reported as research context: what was administered, to which species, by which route, in which study. The goal is a reader who finishes knowing what the literature genuinely establishes about the GH/IGF-1 axis and where it falls silent.